Introduction
Patient engagement has entered a new phase of maturity.
Across two Patients as Partners advisory board discussions, leaders from pharma, CROs, patient advocacy organizations, and community engagement groups described an industry that has largely moved beyond debating the importance of patient voice. The challenge today is operationalizing patient engagement in a way that delivers measurable value, influences decision-making, builds trust, and creates lasting relationships with patients throughout the research lifecycle.
The conversations revealed eight trends that are reshaping how organizations approach patient-centric drug development.
1. Patient Engagement Is Moving From Good Intentions to Measurable Impact
For years, patient engagement programs have been justified largely through mission and values. Increasingly, however, organizations are being asked to demonstrate tangible outcomes. Leaders want to understand whether patient engagement is improving recruitment, retention, protocol design, regulatory interactions, and development decisions.
As budgets tighten and organizations prioritize investments, patient engagement teams are facing the same accountability expectations as other business functions. The question is no longer whether patient engagement matters. The question is how to prove its value.
Organizations are increasingly focused on developing measurement frameworks, defining meaningful success metrics, and connecting patient engagement activities to business and development outcomes.
2. The Industry Is Still Defining What Patient Evidence Matters Most
The volume of patient-generated data continues to grow, but uncertainty remains around how that information influences decision-making.
Advisors repeatedly raised questions around patient-reported outcomes, patient experience data, real-world evidence, eCOAs, and qualitative insights. While regulators consistently signal support for patient-focused development, many organizations still struggle to understand which forms of patient evidence carry the greatest weight and how they are incorporated into regulatory decisions.
This uncertainty is driving demand for greater transparency, stronger case studies, and more practical guidance around how patient evidence is evaluated globally.
3. Trust Has Become a Strategic Business Challenge
Trust was one of the most frequently discussed themes across both advisory meetings.
The conversation has evolved beyond awareness campaigns and communication tactics. Advisors argued that organizations must examine the policies, operating models, and cultural practices that shape patient experiences and perceptions. Trust is increasingly viewed as an organizational outcome rather than a communications objective.
As a result, companies are looking for practical frameworks and case studies that demonstrate how trust can be built, measured, and sustained over time.
4. Patient Advocacy Groups Are Becoming Co-Creators, Not Stakeholders
A notable shift is taking place in the relationship between sponsors and patient advocacy organizations.
Many advocacy groups are no longer serving solely as advisors or recruitment partners. They are increasingly developing frameworks, engagement strategies, educational resources, and best practices that shape how patient engagement is conducted.
This reflects a growing recognition that advocacy organizations often possess expertise around patient needs, lived experience, and community dynamics that sponsors cannot easily replicate. At the same time, organizations are becoming more thoughtful about evaluating which advocacy groups truly represent patient communities and how partnerships should be structured.
5. Recruitment Challenges Continue to Defy Simple Solutions
Despite years of investment, patient recruitment remains one of the most persistent challenges in clinical research.
The discussions highlighted a growing understanding that recruitment is not simply a marketing problem. It is a trust problem, a community engagement problem, and often an operational problem. Sponsors, advocacy organizations, and sites continue to search for more effective ways to reach and support patients throughout the enrollment journey.
Organizations are increasingly recognizing that successful recruitment depends on authentic community relationships, reduced patient burden, and stronger collaboration across stakeholders.
6. Patients Expect Transparency Long After Participation Ends
Patients increasingly want to know what happened after they contributed their time, data, and experiences to research.
Yet advisory board members acknowledged that the industry continues to struggle with how to share results, communicate outcomes, and maintain engagement after participation ends. Regulatory constraints, operational complexity, and legacy processes often create a gap between what patients expect and what organizations can realistically provide.
The result is growing pressure to rethink how organizations approach study results, post-trial communications, and long-term patient relationships.
7. AI Is Creating New Opportunities and New Responsibilities
Artificial intelligence is rapidly becoming part of the patient engagement conversation.
Advisors discussed the potential for AI to support patient education, identify barriers to participation, reduce burden, and personalize engagement strategies. At the same time, concerns around bias, ethics, trust, and equitable implementation remain unresolved.
The organizations that benefit most from AI will likely be those that balance innovation with transparency and patient-centered governance.
8. Patient Engagement Is Moving Earlier and Higher Within Organizations
One of the clearest shifts emerging from the discussions is that patient engagement is moving both earlier in development and higher within organizations.
Participants repeatedly emphasized that patient input often arrives too late to meaningfully influence key decisions. At the same time, several advisors argued that sustainable patient-centricity requires executive sponsorship and leadership accountability. Patient engagement is increasingly being viewed as a strategic function that should influence decisions before protocols are written and before major development investments are made.
Organizations that integrate patient perspectives earlier and elevate patient advocacy leadership are likely to gain the greatest value from patient engagement efforts.
Why These Trends Matter
Taken together, these trends point to a broader transformation occurring across the clinical research ecosystem. Patient engagement is becoming more measurable, more strategic, and more integrated into development decision-making. At the same time, expectations from patients, regulators, advocacy organizations, and communities continue to rise.
The organizations that succeed in this environment will be those that move beyond transactional engagement models and build systems that demonstrate impact, incorporate meaningful patient evidence, strengthen trust, and maintain relationships throughout the research journey. Patient centricity is no longer a standalone initiative. It is increasingly becoming part of how successful development organizations operate.
What Industry Leaders Believe Needs to Happen Next
While the advisory board discussions highlighted significant challenges facing patient-centric drug development, the conversations also revealed a surprising degree of alignment around where the industry should focus its efforts moving forward. Across sponsors, CROs, advocacy organizations, and patient engagement leaders, several priorities consistently emerged as critical to advancing the field.
Move Patient Engagement Earlier in Development
Advisors repeatedly emphasized that patient engagement delivers the greatest value when it occurs before key decisions have been made. Rather than treating patient input as a validation exercise, organizations should incorporate patient perspectives during early development planning, endpoint selection, protocol design, and strategic decision-making. Several participants also stressed that patient engagement must be supported by executive leadership to become fully embedded within organizations.
Establish Clearer Standards for Patient Evidence
The industry needs greater clarity around which forms of patient evidence are most impactful and how that evidence influences regulatory and development decisions. Advisors called for more transparency from regulators, more real-world case studies, and greater alignment around how patient-reported outcomes, patient experience data, qualitative insights, and real-world evidence should be used.
Shift from Engagement Activities to Measurable Outcomes
A recurring recommendation was the need to move beyond counting engagement activities and begin measuring their impact. Advisors encouraged organizations to develop metrics that demonstrate how patient engagement influences recruitment, retention, protocol optimization, decision-making, and organizational performance. The ability to quantify value will be critical to sustaining investment in patient-centric initiatives.
Build Trust Through Operational Change, Not Messaging Alone
While communications remain important, advisors argued that trust is ultimately earned through action. Organizations should focus on reducing patient burden, improving transparency, involving communities earlier, and aligning internal policies and practices with patient needs. Trust-building efforts will be most successful when they are supported across functions rather than owned by a single department.
Strengthen Collaboration Between Sponsors, Advocacy Groups, Sites, and Communities
Many of the challenges discussed, particularly recruitment, community engagement, and patient communications, cannot be solved by a single stakeholder group. Advisors advocated for deeper collaboration across sponsors, patient advocacy organizations, sites, and community partners to create more coordinated and patient-centered approaches to research participation.
Modernize How Results and Research Outcomes Are Shared
One of the strongest areas of consensus centered on transparency. Patients increasingly expect to understand how their participation contributed to research and what outcomes resulted from their involvement. Advisors highlighted the need for clearer expectations during informed consent, more patient-friendly communications, and new approaches to post-trial engagement and results sharing.
Ensure Innovation Remains Patient-Centered
As technologies such as AI become more integrated into research and engagement strategies, advisors stressed the importance of including patient perspectives in their development and implementation. Innovation should be used to reduce burden, improve accessibility, and strengthen engagement while maintaining transparency, trust, and equity.
Looking Ahead
Taken together, these recommendations point toward a future in which patient engagement is more proactive, measurable, collaborative, and integrated into decision-making. The next phase of patient-centric drug development will likely be defined not by whether organizations engage patients, but by how effectively they translate patient insights into action. Organizations that can demonstrate impact, build trust, foster meaningful partnerships, and maintain transparency throughout the research journey will be best positioned to meet the rising expectations of patients, regulators, and the broader healthcare ecosystem.
About Patients as Partners US 2027
The themes and priorities identified throughout these advisory board discussions will be woven throughout the Patients as Partners US 2027 program, bringing together patient advocates, pharmaceutical and biotech leaders, CROs, sites, and patient engagement professionals to explore practical solutions, emerging best practices, and the future of patient-centric drug development.
Patients as Partners US 2027
April 6-7, 2027 | Boston, MA
PatientsasPartnersconference.com